Molecular subtypes of breast cancer predicting clinical benefits of radiotherapy after breast-conserving surgery: a propensity-score-matched cohort study

Table 5 The comparison of distant metastasis incidences between post-BCS patients with and without radiotherapy in each group of molecular subtypes

Subtype	Post-BCS patients after PS match				p value
	RT		No RT
	N	(%)	N	(%)
Luminal A	24	0.91	39	1.50	0.048*
Luminal B/HER2−	13	3.51	12	3.06	0.726
Luminal B/HER2+	21	3.17	30	4.33	0.261
Basal-like	14	3.61	13	3.32	0.828
HER2-enriched	13	3.41	16	4.13	0.599
HR +	58	1.58	81	2.20	0.049*
HR−	27	3.51	29	3.73	0.819

BCS breast-conserving surgery; PS propensity score; HR hormone receptor; RT radiotherapy
Note that patients in RT and No RT cohorts were matched by age, clinical and pathological stage, comorbidities, chemotherapy, hormone therapy, target therapy, anti-cancer agents, and socioeconomic status
*p < 0.05

ISSN: 1465-542X